StockData
TILNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Instil Bio, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$5.79−0.12 (-2.03%)

Close on Oct 19, 2026

Market cap
$39.27M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 12, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 13, 2026During market hours–$-0.63$-0.45
Q1 FY2026
Ended Mar 31, 2026
May 15, 2026Before market open–$-0.62$-0.32
Q4 FY2025
Ended Dec 31, 2025
Mar 27, 2026Before market open–$1.21$0.97
Q3 FY2025
Ended Sep 30, 2025
Nov 13, 2025Before market open––$-1.75
Q2 FY2025
Ended Jun 30, 2025
Aug 13, 2025Before market open–$-3.24$-2.88
Q1 FY2025
Ended Mar 31, 2025
May 13, 2025Before market open–$-4.32$-1.32
Q4 FY2024
Ended Dec 31, 2024
Mar 4, 2025Before market open–$-1.82$-1.08
Q3 FY2024
Ended Sep 30, 2024
Nov 13, 2024Before market open–$-3.54$-2.55
Q2 FY2024
Ended Jun 30, 2024
Aug 13, 2024During market hours–$2.29$1.57
Q1 FY2024
Ended Mar 31, 2024
May 10, 2024Before market open–$3.74$2.39
Q4 FY2023
Ended Dec 31, 2023
Mar 21, 2024During market hours–$-1.99$-1.26

Press releases

Announcements Instil Bio filed with the SEC